Mucinous epithelial tumours arising from ovarian mature teratomas: a tissue genotyping study

Snir, Olivia L.; Buza, Natália; Hui, Pei

doi:10.1111/his.12959

Cited by 16 publications

(9 citation statements)

References 22 publications

(65 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A 33-year-old woman had a morphologically and immunohistochemically compatible SCCOHT in her peri-colonic region 5 years after removal of the ovarian borderline mucinous tumor of the intestinal type 20. A subset of primary ovarian mucinous neoplasm is believed to be associated with teratoma 58. As a collar, the coexistence of mucinous epithelium and SCCOHT might be regarded as a clue to support the germ cell origin of SCCOHT.…”

Section: Histogenesis Of Sccohtmentioning

confidence: 99%

An In-Depth Look at Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT): Clinical Implications from Recent Molecular Findings

Lü¹,

Shi²

2019

J. Cancer

View full text Add to dashboard Cite

Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a highly aggressive cancer in young women. The histogenesis remains unclear although a potential origin of germ cells has been suggested recently. The high throughput next generation sequencing techniques have facilitated the identification of inactivating SMARCA4 mutations as the driver of SCCOHT. These findings may greatly impact on the prevention, diagnosis, molecular classification and treatment of SCCOHTs. The SMARCA4 mutations, typically associated with dual loss of BRG1 and BRM expression, are highly sensitive and specific for the diagnosis of SCCOHT. Germline mutations of SMARCA4 support familial SCCOHT with a critical requirement of genetic counseling and possible prophylactic surgery for carriers. SCCOHT, malignant atypical teratoid/rhabdoid tumors, thoracic sarcomas and some undifferentiated carcinomas harbor rhabdoid morphology and mutations in the SMARC genes, generating an emerging molecular classification of SMARC-mutated tumors. A multi-modality treatment approach consisting of surgery and high dose multi-agent chemotherapy in atypical teratoid/rhabdoid tumors may have potential benefits for SCCOHT patients. Preliminary studies have implicated that the inhibitors targeting EZH2 and the receptor tyrosine kinase, and anti-PD-L1 immunotherapy might be potentially effective for SCCOHT patients. These recent advances on molecular genetics, diagnosis and treatment of SCCOHT address the necessity of multiple institutional collaboration work among oncologist, pathologist, genomic scientist, geneticist, molecular biologist, and pharmacologist.

show abstract

Section: Histogenesis Of Sccohtmentioning

confidence: 99%

An In-Depth Look at Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT): Clinical Implications from Recent Molecular Findings

Lü¹,

Shi²

2019

J. Cancer

View full text Add to dashboard Cite

show abstract

“…As for human epithelial ovarian cancers, the origin of tumor cells has been intensively investigated and proposed to be epithelial cells from fallopian tubes, endometriosis, or mature teratoma [ 2 , 3 ]. By contrast, little is known about the source of CAFs.…”

Section: Introductionmentioning

confidence: 99%

Ovarian stromal cells as a source of cancer-associated fibroblasts in human epithelial ovarian cancer: A histopathological study

et al. 2018

View full text Add to dashboard Cite

Fibroblasts are a major component of cancer tissue and known to contribute to cancer progression. However, it remains unknown whether they are derived from local fibroblasts or of other origin. This study was designed to identify the contribution of local stromal cells to cancer stroma in human epithelial ovarian cancer. Seventy-six cases of surgically resected primary ovarian carcinoma (48 cases confined to the ovaries and 28 cases with distant metastases) and 17 cases of secondary ovarian tumor (e.g. colon cancer metastasized to the ovary) were enrolled in this study. The tissues were immunostained for forkhead box protein L2 (FOXL2), a transcription factor crucial for ovarian development and function, and markers for cancer-associated fibroblasts (CAFs) and inflammatory cells. Under normal condition, FOXL2 expression was restricted to ovarian stromal cells and some other types of cells in female genital tracts and never found in other sites of the body. FOXL2-positive cells were found in all primary and secondary tumors in the ovary, and were the dominant stromal cells in most cases. In contrast, only a few FOXL2-positive cells were found in peritoneal seeding sites of four serous carcinoma cases, and all the other tumors at extraovarian sites had no FOXL2-positive cells. FOXL2-positive cells in the ovarian lesion variably expressed CAFs markers, such as alpha-smooth muscle actin and fibroblast activating protein, as determined by double immunostaining. Background inflammation, but not histological subtype or origin of the neoplasm seemed to correlate with the proportion of FOXL2-positive cells. These results suggest that ovarian stromal cells are the main source of cancer stroma in the ovary but do not seem to move to distant sites via circulation together with tumor cells. Our results also support the hypothesis that cancer-associated fibroblasts may originate locally, which was previously demonstrated using animal models.

show abstract

“…46.6% (n=474) of the cases were right sided, 37.2% (n=379) were left sided while 7.0% (n=71) were bilateral (Table-1). 39.7% (n=404) of the cases were between age group of [20][21][22][23][24][25][26][27][28][29]. Mean size of the tumor was 8.1 +/-3.6 cm, with 60.5% (n=616) cases being between 5 to 10cm.…”

Section: Resultsmentioning

confidence: 99%

“…Our case with a mucinous adenocarcinoma arising in MCT of the ovary was confirmed to have a germ cell origin confirmed by its reactivity for CK-20 immunohistochemical (IHC) stain and negativity for CK-7 IHC stain. 27,28 Ovarian B cell lymphomas are very rare and usually are of primary ovarian origin, without any associated teratoma. The high grade B-cell NHL included in our study was associated with an ovarian MCT.…”

Section: Discussionmentioning

confidence: 99%

Morphological Spectrum of Ovarian Teratomas: A 6 Years Experience at a Specialized Diagnostic Institute

Khalid¹

2021

Proceedings S.Z.M.C

View full text Add to dashboard Cite

Introduction: Ovarian teratomas include mature cystic teratoma (MCT), immature teratoma (IT) and monodermal teratoma (MoT). Malignant transformation (MT) can occur in MCT and MoT, which remains a diagnostic challenge. Aims & Objectives: To discuss the morphological spectrum of ovarian teratomas reported during the last six years at our specialized diagnostic institute and determine the frequency of MT in MCT and MoT. Place and duration of study: The study was carried out at Chughtai Institute of Pathology from January 2015 to December 2020. Material & Methods: A retrospective study was performed by retrieving 1018 cases of ovarian teratomas reported in last 6 years. SPSS version 20 was used for data analysis. Results: MCT was most frequent ovarian teratoma with frequency of 95.6% (n=973), 2.26% (n=23) being IT and 2.16% (n=22) being MoT. IT were mostly seen in pediatric age group. MT in benign MCT was seen in 0.72% of MCT (n=7). Squamous cell carcinoma was most frequent malignancy 71.4% (n=5). One case of MoT also showed MT into papillary thyroid carcinoma, classic type, with frequency of MT in Mot being 4.76% (n=1). All MT in MCT had age >30 years which was a significant finding (p <0.001). Conclusion: Ovarian masses in postmenopausal patients with suspicious radiological features, irrespective of lesional size warrant a thorough gross examination, extensive sampling and a careful microscopic evaluation.

show abstract

Mucinous epithelial tumours arising from ovarian mature teratomas: a tissue genotyping study

Cited by 16 publications

References 22 publications

An In-Depth Look at Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT): Clinical Implications from Recent Molecular Findings

An In-Depth Look at Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT): Clinical Implications from Recent Molecular Findings

Ovarian stromal cells as a source of cancer-associated fibroblasts in human epithelial ovarian cancer: A histopathological study

Morphological Spectrum of Ovarian Teratomas: A 6 Years Experience at a Specialized Diagnostic Institute

Contact Info

Product

Resources

About